Pluripotent embryonic stem cells (ESCs) are unusual in that geminin has been reported to be essential either to prevent differentiation by maintaining expression of pluripotency genes or to prevent DNA rereplication-dependent apoptosis. To distinguish between these two incompatible hypotheses, immune-compromised mice were inoculated subcutaneously with ESCs harboring conditional Gmnn alleles alone or together with a tamoxifen-dependent Cre recombinase gene. Mice were then injected with tamoxifen at various times during which the ESCs proliferated and differentiated into a teratoma. For comparison, the same ESCs were cultured in vitro in the presence of monohydroxytamoxifen. The results revealed that geminin is a haplosufficient gene that is essential for ESC viability before they differentiate into a teratoma, but once a teratoma is established, the differentiated cells can continue to proliferate in the absence of Gmnn alleles, geminin protein, and pluripotent stem cells. Thus, differentiated cells did not require geminin for efficient proliferation within the context of a solid tissue, although they did when teratoma cells were cultured in vitro. These results provide proof-of-principle that preventing geminin function could prevent malignancy in tumors derived from pluripotent cells by selectively eliminating the progenitor cells with little harm to normal cells.
Get full access to this article
View all access options for this article.
References
1.
BoroviakT, LoosR, BertoneP, SmithA and NicholsJ. (2014). The ability of inner-cell-mass cells to self-renew as embryonic stem cells is acquired following epiblast specification. Nat Cell Biol, 16:516–528.
2.
TangF, BarbacioruC, BaoS, LeeC, NordmanE, WangX, LaoK and SuraniMA. (2010). Tracing the derivation of embryonic stem cells from the inner cell mass by single-cell RNA-Seq analysis. Cell Stem Cell, 6:468–478.
3.
Bulic-JakusF, Katusic BojanacA, Juric-LekicG, VlahovicM and SincicN. (2016). Teratoma: from spontaneous tumors to the pluripotency/malignancy assay. Wiley Interdiscip Rev Dev Biol, 5:186–209.
4.
CunninghamJJ, UlbrightTM, PeraMF and LooijengaLH. (2012). Lessons from human teratomas to guide development of safe stem cell therapies. Nat Biotechnol, 30:849–857.
5.
EconomouC, TsakiridisA, WymeerschFJ, Gordon-KeylockS, DewhurstRE, FisherD, MedvinskyA, SmithAJ and WilsonV. (2015). Intrinsic factors and the embryonic environment influence the formation of extragonadal teratomas during gestation. BMC Dev Biol, 15:35.
6.
JacksonSA, SchiesserJ, StanleyEG and ElefantyAG. (2010). Differentiating embryonic stem cells pass through ‘temporal windows’ that mark responsiveness to exogenous and paracrine mesendoderm inducing signals. PLoS One, 5:e10706.
7.
ThomsonM, LiuSJ, ZouLN, SmithZ, MeissnerA and RamanathanS. (2011). Pluripotency factors in embryonic stem cells regulate differentiation into germ layers. Cell, 145:875–889.
8.
SolterD. (2006). From teratocarcinomas to embryonic stem cells and beyond: a history of embryonic stem cell research. Nat Rev Genet, 7:319–327.
9.
SaitouM and YamajiM. (2012). Primordial germ cells in mice. Cold Spring Harb Perspect Biol, 4. a008375.
10.
KimJ and OrkinSH. (2011). Embryonic stem cell-specific signatures in cancer: insights into genomic regulatory networks and implications for medicine. Genome Med, 3:75.
11.
PalmerNP, SchmidPR, BergerB and KohaneIS. (2012). A gene expression profile of stem cell pluripotentiality and differentiation is conserved across diverse solid and hematopoietic cancers. Genome Biol, 13:R71.
12.
Ben-PorathI, ThomsonMW, CareyVJ, GeR, BellGW, RegevA and WeinbergRA. (2008). An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet, 40:499–507.
13.
Ben-DavidU and BenvenistyN. (2011). The tumorigenicity of human embryonic and induced pluripotent stem cells. Nat Rev Cancer, 11:268–277.
14.
ValentP, BonnetD, De MariaR, LapidotT, CoplandM, MeloJV, ChomienneC, IshikawaF, SchuringaJJ, et al. (2012). Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer, 12:767–775.
15.
AbbasT, KeatonMA and DuttaA. (2013). Genomic instability in cancer. Cold Spring Harb Perspect Biol, 5:a012914.
16.
BlowJJ and GillespiePJ. (2008). Replication licensing and cancer—a fatal entanglement?. Nat Rev Cancer, 8:799–806.
17.
LutzmannM, MaioranoD and MechaliM. (2006). A Cdt1-geminin complex licenses chromatin for DNA replication and prevents rereplication during S phase in Xenopus. EMBO J, 25:5764–5774.
18.
KrollKL. (2007). Geminin in embryonic development: coordinating transcription and the cell cycle during differentiation. Front Biosci, 12:1395–1409.
19.
de RentyC, KanekoKJ and DePamphilisML. (2014). The dual roles of geminin during trophoblast proliferation and differentiation. Dev Biol, 387:49–63.
20.
GonzalezMA, TachibanaKE, AdamsDJ, van der WeydenL, HembergerM, ColemanN, BradleyA and LaskeyRA. (2006). Geminin is essential to prevent endoreduplication and to form pluripotent cells during mammalian development. Genes Dev, 20:1880–1884.
21.
HaraK, NakayamaKI and NakayamaK. (2006). Geminin is essential for the development of preimplantation mouse embryos. Genes Cells, 11:1281–1293.
22.
HuangYY, KanekoKJ, PanH and DePamphilisML. (2015). Geminin is essential to prevent DNA re-replication-dependent apoptosis in pluripotent cells, but not in differentiated cells. Stem Cells, 33:3239–3253.
23.
PattersonES, WallerLE and KrollKL. (2014). Geminin loss causes neural tube defects through disrupted progenitor specification and neuronal differentiation. Dev Biol, 393:44–56.
24.
SchultzKM, BanisadrG, LastraRO, McGuireT, KesslerJA, MillerRJ and McGarryTJ. (2011). Geminin-deficient neural stem cells exhibit normal cell division and normal neurogenesis. PLoS One, 6:e17736.
25.
ShinnickKM, EklundEA and McGarryTJ. (2010). Geminin deletion from hematopoietic cells causes anemia and thrombocytosis in mice. J Clin Invest, 120:4303–4315.
TabriziGA, BoseK, ReimannY and KesselM. (2013). Geminin is required for the maintenance of pluripotency. PLoS One, 8:e73826.
28.
YangVS, CarterSA, HylandSJ, Tachibana-KonwalskiK, LaskeyRA and GonzalezMA. (2011). Geminin escapes degradation in G1 of mouse pluripotent cells and mediates the expression of Oct4, Sox2, and Nanog. Curr Biol, 21:692–699.
29.
YellajoshyulaD, PattersonES, ElittMS and KrollKL. (2011). Geminin promotes neural fate acquisition of embryonic stem cells by maintaining chromatin in an accessible and hyperacetylated state. Proc Natl Acad Sci U S A, 108:3294–3299.
30.
SlawnyN and O'SheaKS. (2013). Geminin promotes an epithelial-to-mesenchymal transition in an embryonic stem cell model of gastrulation. Stem Cells Dev, 22:1177–1189.
31.
NakuciE, XuM, PujanaMA, VallsJ and ElshamyWM. (2006). Geminin is bound to chromatin in G2/M phase to promote proper cytokinesis. Int J Biochem Cell Biol, 38:1207–1220.
32.
Di MiccoR, CicaleseA, FumagalliM, DobrevaM, VerrecchiaA, PelicciPG and di FagagnaF. (2008). DNA damage response activation in mouse embryonic fibroblasts undergoing replicative senescence and following spontaneous immortalization. Cell Cycle, 7:3601–3606.
Klotz-NoackK, McIntoshD, SchurchN, PrattN and BlowJJ. (2012). Re-replication induced by geminin depletion occurs from G2 and is enhanced by checkpoint activation. J Cell Sci, 125:2436–2445.
35.
ZhuW and DepamphilisML. (2009). Selective killing of cancer cells by suppression of geminin activity. Cancer Res, 69:4870–4877.
36.
VassilevA, LeeCY, VassilevB, ZhuW, OrmanogluP, MartinSE and DePamphilisML. (2016). Identification of genes that are essential to restrict genome duplication to once per cell division. Oncotarget, 7:34956–34976.
37.
MullenP. (2004). The use of Matrigel to facilitate the establishment of human cancer cell lines as xenografts. Methods Mol Med, 88:287–292.
38.
LallemandY, MoreauJ, ClomentCS, VivesFL and RobertB. (2013). Generation and characterization of a tamoxifen inducible Msx1(CreERT2) knock-in allele. Genesis, 51:110–119.
39.
LiuY, SuckaleJ, MasjkurJ, MagroMG, SteffenA, AnastassiadisK and SolimenaM. (2010). Tamoxifen-independent recombination in the RIP-CreER mouse. PLoS One, 5:e13533.
40.
RonzaudC, LoffingJ, GretzN, SchutzG and BergerS. (2011). Inducible renal principal cell-specific mineralocorticoid receptor gene inactivation in mice. Am J Physiol Renal Physiol, 300:F756–F760.
41.
Bustamante-MarinX, GarnessJA and CapelB. (2013). Testicular teratomas: an intersection of pluripotency, differentiation and cancer biology. Int J Dev Biol, 57:201–210.
42.
JonesTD, UlbrightTM, EbleJN, BaldridgeLA and ChengL. (2004). OCT4 staining in testicular tumors: a sensitive and specific marker for seminoma and embryonal carcinoma. Am J Surg Pathol, 28:935–940.
43.
JonesTD, UlbrightTM, EbleJN and ChengL. (2004). OCT4: a sensitive and specific biomarker for intratubular germ cell neoplasia of the testis. Clin Cancer Res, 10:8544–8547.
44.
InwaldEC, Klinkhammer-SchalkeM, HofstadterF, ZemanF, KollerM, GerstenhauerM and OrtmannO. (2013). Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat, 139:539–552.
45.
OzolekJA and CastroCA. (2011). Teratomas derived from embryonic stem cells as models for embryonic development, disease, and tumorigenesis. In: Embryonic Stem Cells - Basic Biology to Bioengineering. KallosM, ed. InTech. www.intechopen.com/books/embryonic-stem-cells-basic-biology-to-bioengineering/teratomas-derived-from-embryonic-stem-cells-as-models-for-embryonic-development-disease-and-tumorige. INTECH, 231–262.
46.
GargV, MorganiS and HadjantonakisAK. (2016). Capturing identity and fate ex vivo: stem cells from the mouse blastocyst. Curr Top Dev Biol, 120:361–400.
47.
BronsIG, SmithersLE, TrotterMW, Rugg-GunnP, SunB, Chuva de Sousa LopesSM, HowlettSK, ClarksonA, Ahrlund-RichterL, PedersenRA and VallierL. (2007). Derivation of pluripotent epiblast stem cells from mammalian embryos. Nature, 448:191–195.
48.
KlineRC and Bazzett-MatabeleLB. (2010). Adnexal masses and malignancies of importance to the colorectal surgeon. Clin Colon Rectal Surg, 23:63–71.
49.
OosterhuisJW, StoopH, HoneckerF and LooijengaLH. (2007). Why human extragonadal germ cell tumours occur in the midline of the body: old concepts, new perspectives. Int J Androl, 30:256–263; discussion 263–264.
OsornoR, TsakiridisA, WongF, CambrayN, EconomouC, WilkieR, BlinG, ScottingPJ, ChambersI and WilsonV. (2012). The developmental dismantling of pluripotency is reversed by ectopic Oct4 expression. Development, 139:2288–2298.
52.
HayashiK, OhtaH, KurimotoK, AramakiS and SaitouM. (2011). Reconstitution of the mouse germ cell specification pathway in culture by pluripotent stem cells. Cell, 146:519–532.
53.
MatsuiY, ZseboK and HoganBL. (1992). Derivation of pluripotential embryonic stem cells from murine primordial germ cells in culture. Cell, 70:841–847.
54.
ResnickJL, BixlerLS, ChengL and DonovanPJ. (1992). Long-term proliferation of mouse primordial germ cells in culture. Nature, 359:550–551.
55.
ShamblottMJ, AxelmanJ, WangS, BuggEM, LittlefieldJW, DonovanPJ, BlumenthalPD, HugginsGR and GearhartJD. (1998). Derivation of pluripotent stem cells from cultured human primordial germ cells. Proc Natl Acad Sci U S A, 95:13726–13731.
56.
BarryKA, SchultzKM, PayneCJ and McGarryTJ. (2012). Geminin is required for mitotic proliferation of spermatogonia. Dev Biol, 371:35–46.
57.
LooijengaLH, StoopH, de LeeuwHP, de Gouveia BrazaoCA, GillisAJ, van RoozendaalKE, van ZoelenEJ, WeberRF, WolffenbuttelKP, et al. (2003). POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors. Cancer Res, 63:2244–2250.
58.
RabbanJT and ZaloudekCJ. (2013). A practical approach to immunohistochemical diagnosis of ovarian germ cell tumours and sex cord-stromal tumours. Histopathology, 62:71–88.
59.
EvansMJ and KaufmanMH. (1981). Establishment in culture of pluripotential cells from mouse embryos. Nature, 292:154–156.
60.
MartinGR. (1981). Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. Proc Natl Acad Sci U S A, 78:7634–7638.
61.
LimCY, SolterD, KnowlesBB and DamjanovI. (2015). Development of teratocarcinomas and teratomas in severely immunodeficient NOD.Cg-Prkdc(scid) Il2rg(tm1Wjl)/Szj (NSG) mice. Stem Cells Dev, 24:1515–1520.
62.
KaramitrosD, PatmanidiAL, KotantakiP, PotocnikAJ, Bahr-IvacevicT, BenesV, LygerouZ, KioussisD and TaravirasS. (2015). Geminin deletion increases the number of fetal hematopoietic stem cells by affecting the expression of key transcription factors. Development, 142:70–81.
63.
KaramitrosD, KotantakiP, LygerouZ, Veiga-FernandesH, PachnisV, KioussisD and TaravirasS. (2010). Differential geminin requirement for proliferation of thymocytes and mature T cells. J Immunol, 184:2432–2441.
64.
ZhuW, ChenY and DuttaA. (2004). Rereplication by depletion of geminin is seen regardless of p53 status and activates a G2/M checkpoint. Mol Cell Biol, 24:7140–7150.
65.
Di BonitoM, CantileM, CollinaF, ScognamiglioG, CerroneM, La MantiaE, BarbatoA, LiguoriG and BottiG. (2012). Overexpression of cell cycle progression inhibitor geminin is associated with tumor stem-like phenotype of triple-negative breast cancer. J Breast Cancer, 15:162–171.
66.
KimHE, KimDG, LeeKJ, SonJG, SongMY, ParkYM, KimJJ, ChoSW, ChiSG, et al. (2012). Frequent amplification of CENPF, GMNN and CDK13 genes in hepatocellular carcinomas. PLoS One, 7:e43223.
RagoC, HusoDL, DiehlF, KarimB, LiuG, PapadopoulosN, SamuelsY, VelculescuVE, VogelsteinB, KinzlerKW and DiazLAJr. (2007). Serial assessment of human tumor burdens in mice by the analysis of circulating DNA. Cancer Res, 67:9364–9370.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
